Back to Journals » Drug Design, Development and Therapy » Volume 15

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date

Total article views   HTML views PDF downloads Totals
7,614 Dovepress* 6,300+ 506 6,806
PubMed Central* 1,314 223 1,537
Totals 7,614 729 8,343
*Since 14 July 2021
Total mentioned Facebook Delicious Reddit Twitter Others
6 0 0 0 3 3

View citations on PubMed Central and Google Scholar